2-(2-aminothiazol-4-yl)propan-2-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-aminothiazol-4-yl)propan-2-ol
• 英文别名: 2-(2-amino-1,3-thiazol-4-yl)propan-2-ol
• 化学式: C₆H₁₀N₂OS
• 分子量: 158.224
• InChiKey: NRQGTTQZNNQWJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  87.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-aminothiazol-4-yl)propan-2-ol 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 2-(2-((2-chloro-5-((trimethylsilyl)ethynyl)pyrimidin-4-yl)amino)thiazol-4-yl)propan-2-ol
  参考文献：
  名称：

  作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用

  摘要：

  本发明公开了具有WEE1靶点抑制活性的新型嘧啶并杂环类化合物，具体公开了作为WEE1靶点抑制剂的具有式(I)结构所示化合物或其药学上可接受的盐、溶剂合物、水合物、同位素取代物或其异构体。

  公开号：

  WO2023217201A2
• 作为产物：
  描述：

  2-氨基噻唑-4-甲酸乙酯 、 甲基氯化镁 以 四氢呋喃 为溶剂， 反应 2.0h， 以60%的产率得到2-(2-aminothiazol-4-yl)propan-2-ol
  参考文献：
  名称：

  WO2019201865A5

  摘要：

  公开号：

  WO2019201865A5

文献信息

• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• Heteroarylcarbamoylbenzene derivative
  申请人：IIno Tomoharu

  公开号：US20060167053A1

  公开（公告）日：2006-07-27

  Compounds represented by formula (I): as well as their pharmaceutically acceptable salts are disclosed. The compounds are useful as glucokinase activating agents for the treatment of diabetes and related conditions. Compositions and methods of treatment are also included.

  公式（I）所代表的化合物及其药学上可接受的盐被披露。这些化合物可用作激活葡萄糖激酶的药剂，用于治疗糖尿病及相关疾病。还包括治疗组合物和方法。
• Heteroarylcarbamoylbenzene derivatives
  申请人：Iino Tomoharu

  公开号：US20090018056A1

  公开（公告）日：2009-01-15

  Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein X 1 represents oxygen, etc., X 2 represents oxygen, etc., R 1 represents a group on Ring A such as alkylsulfonyl, etc., R 2 represents C3-7 cyclic alkyl optionally substituted with a halogen, etc., R 3 represents a substituent on Ring B such as lower alkyl, etc., formula (II): [Chemical Formula 1] represents 6- to 10-membered aryl, etc., and formula (III): [Formula 1] represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by R 3 above, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C═N bond with the nitrogen atom of the ring], as well as their pharmaceutically acceptable salts.

  具有激活葡萄糖激酶效果且可用作糖尿病治疗的化合物，其化学式如下（I）：[其中X1代表氧等，X2代表氧等，R1代表环A上的基团，例如烷基磺酰等，R2代表C3-7环状烷基，可选择地被卤素等取代，R3代表环B上的取代基，例如低烷基等，化学式（II）：[化学式1]代表6到10成员芳基等，化学式（III）：[化学式1]代表单环或双环杂芳基，可选择地在环B上具有由上述R3代表的取代基，其中环B的碳原子与化学式（I）的酰胺基团的氮原子形成C═N键与环的氮原子结合]，以及其药学上可接受的盐。
• NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME
  申请人：KOWA COMPANY, LTD.

  公开号：US20140309207A1

  公开（公告）日：2014-10-16

  The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R 1 and R 2 , which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C 1-6 alkyl group, a C 6-10 aryl group, a cyano group, a C 1-6 alkyl group optionally having a substituent, a C 2-6 alkenyl group optionally having a substituent, etc.; R 3 represents a hydrogen atom, a C 1-6 alkyl group optionally having a substituent, etc.; and R 4 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group optionally having a substituent, etc.]

  本发明提供了一种新型化合物，其通式（1）如下所示，具有在肝脏和胰岛β细胞中激活葡萄糖激酶的作用，并可用作预防和/或治疗由高血糖引起的疾病，如糖尿病的药物。该通式（1）表示的螺环吲哚化合物，或其盐，或化合物或盐的溶剂：[其中环A代表含氮的5-10成员杂环基；R1和R2，相同或不同，分别代表氢原子，卤原子，卤代C1-6烷基，C6-10芳基，氰基，C1-6烷基，可选取代基，C2-6烯基，可选取代基等；R3代表氢原子，C1-6烷基，可选取代基等；R4代表氢原子，卤原子，C1-6烷基，可选取代基等。]
• SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES
  申请人：Masarykova univerzita

  公开号：EP3556755A1

  公开（公告）日：2019-10-23

  The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

  本发明提供了结构式（1）所代表的化合物： 其中 R1、R2、R3、R4、R5、R6 如权利要求中定义。这些化合物是核酸酶的抑制剂，特别适用于增殖性疾病、神经退行性疾病和其他基因组不稳定性相关疾病的治疗和/或预防方法。